Dr. Marshall on HER2 Amplification in Colorectal Cancer
April 8th 2019John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses HER2 amplification in colorectal cancer (CRC).
Dr. Weinberg on Broad Molecular Profiling in GI Cancers
March 7th 2019Benjamin Weinberg, MD, assistant professor of medicine, Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, discusses the importance of broad molecular profiling in patients with gastrointestinal cancers.
Dr. Marshall on Personalized Chemotherapy in CRC
March 5th 2019John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses personalized chemotherapy in the treatment of patients with colorectal cancer.
Dr. Weinberg Discusses the Use of FOLFIRINOX in Older Patients With Metastatic Pancreatic Cancer
February 26th 2019Benjamin Weinberg, MD, assistant professor of medicine, Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, discusses the use of FOLFIRINOX in older patients with metastatic pancreatic cancer.
Dr. Pishvaian Discusses Atezolizumab Plus Bevacizumab in HCC
November 2nd 2018Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with hepatocellular carcinoma.
Dr. Isaacs Discusses Antibody Drug Conjugates in TNBC
March 1st 2018Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses antibody drug conjugates in the treatment of patients with triple-negative breast cancer.
Expert Highlights Progress With Molecular Biomarkers in GI Cancers
March 1st 2018Michael J. Pishvaian, MD, discusses expanded testing for biomarkers, using liquid biopsies to predict response to treatment, and the importance of identifying increasingly specific subsets of GI cancers to make treatment decisions.
Dr. Pishvaian on the Future of Entrectinib in Pancreatic Cancer
February 20th 2018Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses the future of entrectinib in the treatment of patients with pancreatic cancer.
Dr. Marshall on Single-Agent and Combination Immunotherapy Applications in MSI-H mCRC
February 15th 2018John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses the progression of immunotherapy in colon cancer.
Dr. Isaacs Discusses the Future of Treatment for HER2+ Breast Cancer
February 14th 2018Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses the future of treatment for patients with HER2-positive breast cancer.
Dr. Pishvaian on Precision Medicine in GI Cancer
February 13th 2018Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses the use of precision medicine, specifically molecular profiling in patients with gastrointestinal (GI) cancers.
Dr. Marshall on the Importance of Testing for BRAF Mutations in mCRC
February 12th 2018John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the specificity now required in the treatment of patients with metastatic colorectal cancer (mCRC).
Dr. Isaacs Discusses Sacituzumab Govitecan in TNBC
February 5th 2018Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses sacituzumab govitecan (IMMU-132) for the treatment of patients with triple-negative breast cancer.
Dr. Isaacs Discusses the Role of Neratinib in HER2+ Breast Cancer
January 26th 2018Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses the role of neratinib (Nerlynx) in the treatment landscape of HER2-positive breast cancer.